BRIEF published on 02/12/2025 at 07:35, 1 year 3 months ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
BRIEF published on 01/23/2025 at 18:50, 1 year 4 months ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 4 months ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 1 year 4 months ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 4 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
BRIEF published on 12/24/2024 at 20:51, 1 year 5 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 5 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
BRIEF published on 11/13/2024 at 07:35, 1 year 6 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
Published on 06/03/2026 at 13:25, 14 minutes ago Metallic Minerals Announces Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$10 Million
Published on 06/03/2026 at 13:00, 39 minutes ago CoTec Holdings Corp. Joint Venture, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub
Published on 06/03/2026 at 10:30, 3 hours 9 minutes ago Silver Range Partner Excalibur Metals Intersects a Broad Precious Metals Zone, Open at Depth at the Bellehelen Property
Published on 06/03/2026 at 10:00, 3 hours 39 minutes ago Eagle Plains and Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, SK
Published on 06/03/2026 at 13:23, 16 minutes ago CEWE: Annual General Meeting approves 17th consecutive dividend increase
Published on 06/03/2026 at 13:18, 21 minutes ago EQS-Adhoc: Klöckner & Co SE: Decision to launch a delisting tender offer of Worthington Steel at €11.00 per Klöckner & Co-Share published
Published on 06/03/2026 at 13:10, 29 minutes ago SensorUp Closes Growth Financing to Scale its Agentic Operations Platform for Heavy Industry
Published on 06/03/2026 at 12:45, 54 minutes ago Hong Kong forges new opportunities with Kazakhstan and Central Asia
Published on 06/03/2026 at 12:40, 59 minutes ago Infosys and LTA Launch AI-Driven Match and Fan Experiences at the HSBC Championships, and Beyond
Published on 06/03/2026 at 12:41, 58 minutes ago Disclosure of Share Capital and Voting Rights as of Mai 31, 2026
Published on 06/03/2026 at 11:29, 2 hours 10 minutes ago 2026.06.03 Notice to holders of the Convertible Bond ISIN FR0013521085
Published on 06/03/2026 at 08:45, 4 hours 54 minutes ago Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project
Published on 06/02/2026 at 18:03, 19 hours 36 minutes ago Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 19 hours 57 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
